The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses

European Journal of Immunology

Volumn 42, Issue 10, 2012, Pages 2709-2719

  Mori, Andres ^a   Oleszycka, Ewa ^a   Sharp, Fiona A ^a   Coleman, Michelle ^a   Ozasa, Yuki ^a   Singh, Manmohan ^b   O'Hagan, Derek T ^b   Tajber, Lidia ^a   Corrigan, Owen I ^a   McNeela, Edel A ^a   Lavelle, Ed C ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b Novartis Vaccines Cambridge   (United States)

Author keywords

Adjuvant; Alum; IL 12; Inflammasome; Vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CHITOSAN; CPG OLIGODEOXYNUCLEOTIDE; INFLAMMASOME; INTERLEUKIN 12; INTERLEUKIN 12P35; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CPG ISLAND; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG MECHANISM; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; TH17 CELL;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; CELLS, CULTURED; CHITOSAN; DENDRITIC CELLS; FEMALE; GENE EXPRESSION REGULATION; IMMUNITY, CELLULAR; INTERLEUKIN-12 SUBUNIT P35; MICE; MICE, INBRED C57BL; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; TH1 CELLS; TH17 CELLS;

EID: 84867209994     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201242372     Document Type: Article

References (44)

1. Rappuoli, R. and Aderem, A., A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 2011. 473: 463-469.
2. Brewer, J. M., Conacher, M., Hunter, C. A., Mohrs, M., Brombacher, F. and Alexander, J., Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J. Immunol. 1999. 163: 6448-6454.
3. Jordan, M. B., Mills, D. M., Kappler, J., Marrack, P. and Cambier, J. C., Promotion of B cell immune responses via an alum-induced myeloid cell population. Science 2004. 304: 1808-1810.
4. Steinman, R. M., Decisions about dendritic cells: past, present, and future. Annu. Rev. Immunol. 2011.
5. Eisenbarth, S. C., Colegio, O. R., O'Connor, W., Sutterwala, F. S. and Flavell, R. A., Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008. 453: 1122-1126.
6. Sharp, F. A., Ruane, D., Claass, B., Creagh, E., Harris, J., Malyala, P., Singh, M. et al., Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc. Natl. Acad. Sci. USA 2009. 106: 870-875.
7. Harris, J., Sharp, F. A. and Lavelle, E. C., The role of inflammasomes in the immunostimulatory effects of particulate vaccine adjuvants. Eur. J. Immunol. 2010. 40: 634-638.
8. Kool, M., Soullie, T., van Nimwegen, M., Willart, M. A., Muskens, F., Jung, S., Hoogsteden, H. C. et al., Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med. 2008. 205: 869-882.
9. Kool, M., Willart, M. A., van Nimwegen, M., Bergen, I., Pouliot, P., Virchow, J. C., Rogers, N. et al., An unexpected role for uric acid as an inducer of T helper 2 cell immunity to inhaled antigens and inflammatory mediator of allergic asthma. Immunity 2011. 34: 527-540.
10. Kaufmann, S. H. and McMichael, A. J., Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat. Med. 2005. 11: S33-S44.
11. Stevenson, M. M. and Riley, E. M., Innate immunity to malaria. Nat. Rev. Immunol. 2004. 4: 169-180.
12. Trinchieri, G., Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 2003. 3: 133-146.
13. Khader, S. A., Gaffen, S. L. and Kolls, J. K., Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol. 2009. 2: 403-411.
14. Lin, Y., Ritchea, S., Logar, A., Slight, S., Messmer, M., Rangel-Moreno, J., Guglani, L. et al., Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity 2009. 31: 799-810.
15. Dong, C., TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat. Rev. Immunol. 2008. 8: 337-348.
16. Sutton, C., Brereton, C., Keogh, B., Mills, K. H. and Lavelle, E. C., A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 2006. 203: 1685-1691.
17. Chung, Y., Chang, S. H., Martinez, G. J., Yang, X. O., Nurieva, R., Kang, H. S., Ma, L. et al., Critical regulation of early Th17-cell differentiation by interleukin-1 signaling. Immunity 2009. 30: 576-587.
18. Khader, S. A., Bell, G. K., Pearl, J. E., Fountain, J. J., Rangel-Moreno, J., Cilley, G. E., Shen, F. et al., IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T-cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol. 2007. 8: 369-377.
19. Jankovic, D., Caspar, P., Zweig, M., Garcia-Moll, M., Showalter, S. D., Vogel, F. R. and Sher, A., Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120. J. Immunol. 1997. 159: 2409-2417.
20. Didierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A. et al., AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 2009. 183: 6186-6197.
21. Garcon, N., Chomez, P. and Van Mechelen, M., GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines 2007. 6: 723-739.
22. Baudner, B. C., Ronconi, V., Casini, D., Tortoli, M., Kazzaz, J., Singh, M., Hawkins, L. D. et al., MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm. Res. 2009. 26: 1477-1485.
23. Hutchison, S., Benson, R. A., Gibson, V. B., Pollock, A. H., Garside, P. and Brewer, J. M., Antigen depot is not required for alum adjuvanticity. FASEB J. 2011.
24. Flach, T. L., Ng, G., Hari, A., Desrosiers, M. D., Zhang, P., Ward, S. M., Seamone, M. E. et al., Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat. Med. 2011. 17: 479-487.
25. Fukao, T., Tanabe, M., Terauchi, Y., Ota, T., Matsuda, S., Asano, T., Kadowaki, T. et al., PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat. Immunol. 2002. 3: 875-881.
26. Kuroda, E., Ishii, K. J., Uematsu, S., Ohata, K., Coban, C., Akira, S., Aritake, K. et al., Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. Immunity 2011. 34: 514-526.
27. Kalinski, P., Vieira, P. L., Schuitemaker, J. H., de Jong, E. C. and Kapsenberg, M. L., Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood 2001. 97: 3466-3469.
28. Krieg, A. M., Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug. Discov. 2006. 5: 471-484.
29. MacLeod, M. K., McKee, A. S., David, A., Wang, J., Mason, R., Kappler, J. W. and Marrack, P., Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells. Proc. Natl. Acad. Sci. USA 2011. 108: 7914-7919.
30. Ng, G., Sharma, K., Ward, S. M., Desrosiers, M. D., Stephens, L. A., Schoel, W. M., Li, T. et al., Receptor-independent, direct membrane binding leads to cell-surface lipid sorting and Syk kinase activation in dendritic cells. Immunity 2008. 29: 807-818.
31. Wack, A., Baudner, B. C., Hilbert, A. K., Manini, I., Nuti, S., Tavarini, S., Scheffczik, H. et al., Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 2007.
32. Guy, B., The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol. 2007. 5: 505-517.
33. Kundi, M., New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev. Vaccines 2007. 6: 133-140.
34. Paavonen, J., Jenkins, D., Bosch, F. X., Naud, P., Salmeron, J., Wheeler, C. M., Chow, S. N. et al., Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007. 369: 2161-2170.
35. Weiner, G. J., Liu, H. M., Wooldridge, J. E., Dahle, C. E. and Krieg, A. M., Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. USA 1997. 94: 10833-10837.
36. Chu, R. S., Targoni, O. S., Krieg, A. M., Lehmann, P. V. and Harding, C. V., CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 1997. 186: 1623-1631.
37. Narita, K., Hu, D. L., Mori, F., Wakabayashi, K., Iwakura, Y. and Nakane, A., Role of interleukin-17A in cell-mediated protection against Staphylococcus aureus infection in mice immunized with the fibrinogen-binding domain of clumping factor A. Infect Immun. 2010. 78: 4234-4242.
38. Hogenesch, H., Dunham, A., Hansen, B., Anderson, K., Maisonneuve, J. F. and Hem, S. L., Formulation of a killed whole cell pneumococcus vaccine - effect of aluminum adjuvants on the antibody and IL-17 response. J. Immune. Based Ther. Vaccines 2011. 9: 5.
39. Pedra, J. H., Sutterwala, F. S., Sukumaran, B., Ogura, Y., Qian, F., Montgomery, R. R., Flavell, R. A. et al., ASC/PYCARD and caspase-1 regulate the IL-18/IFN-gamma axis during Anaplasma phagocytophilum infection. J. Immunol. 2007. 179: 4783-4791.
40. Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K. et al., Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 2009. 15: 1170-1178.
41. Martin-Orozco, N., Muranski, P., Chung, Y., Yang, X. O., Yamazaki, T., Lu, S., Hwu, P. et al., T helper 17 cells promote cytotoxic T-cell activation in tumor immunity. Immunity 2009. 31: 787-798.
42. Heit, A., Schmitz, F., Haas, T., Busch, D. H. and Wagner, H., Antigen co-encapsulated with adjuvants efficiently drive protective T-cell immunity. Eur. J. Immunol. 2007. 37: 2063-2074.
43. Lutz, M. B., Kukutsch, N., Ogilvie, A. L., Rossner, S., Koch, F., Romani, N. and Schuler, G., An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 1999. 223: 77-92.
44. Singh, M., Kazzaz, J., Chesko, J., Soenawan, E., Ugozzoli, M., Giuliani, M., Pizza, M. et al., Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. J. Pharm. Sci. 2004. 93: 273-282.